A Canadian Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus CAN-TREAT (CANadian TREsiba AudiT)
Phase of Trial: Phase IV
Latest Information Update: 14 Jun 2019
Price : $35 *
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CAN-TREAT
- Sponsors Novo Nordisk
- 15 May 2019 Status changed from recruiting to completed.
- 26 Apr 2019 Planned End Date changed from 15 Apr 2019 to 30 Apr 2019.
- 26 Apr 2019 Planned primary completion date changed from 15 Apr 2019 to 30 Apr 2019.